SCHEMBL24717994

SCHEMBL24717994

COC(=O)c1ccc(C2CCN(C(=O)OC(C)(C)C)CC2(F)F)cc1C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 8/20 0.42
EED O75530 1/20 0.42
RBBP4 Q09028 1/20 0.42
SUZ12 Q15022 1/20 0.42
EZH2 Q15910 1/20 0.42
AEBP2 Q6ZN18 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42
ALDH1A1 P00352 1/20 0.40
PDE4B Q07343 1/20 0.40
EPHX2 P34913 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ABL1 P00519 1/20 0.39
RIN1 Q13671 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
GPR119 Q8TDV5 2/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30798392 1.00 STS (0.42) STSEEDRBBP4SUZ12EZH2
SCHEMBL29152565 0.95 STS (0.40) STSEEDRBBP4SUZ12EZH2
SCHEMBL30798543 0.91 STS (0.40) STSEEDRBBP4SUZ12EZH2
SCHEMBL16991921 0.91 PDE4B (0.46) STSEEDRBBP4SUZ12EZH2
SCHEMBL30606461 0.91 PDE4B (0.46) STSEEDRBBP4SUZ12EZH2
SCHEMBL22551229 0.86 KMT2A (0.43) STSPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL18310138 0.84 PDE4B (0.47) STSPTPN2PTPN1PTPN6ALDH1A1
SCHEMBL16874571 0.81 ALDH1A1 (0.55) STSALDH1A1PDE4BEPHX2GPR119
SCHEMBL16874573 0.81 ALDH1A1 (0.55) STSALDH1A1PDE4BEPHX2GPR119
SCHEMBL16611368 0.81 RORC (0.43) STSPTPN2PTPN1PTPN6GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117279910-A Modulators of BCL6 proteolysis and related methods of use 阿尔维纳斯运营股份有限公司 2023-12-22 CN disclosed
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 STS 4320/4885EED 1242/4885RBBP4 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.